REGINfo: Biogen Idec Inc - Biotechnologie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- FRUTAROM
- GAZIT GLOBE
- HAREL
- ICL
- ISRAEL CORP
- LEUMI
- MAZOR ROBOTICS
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- POALIM
- SHUFERSAL
- SODASTREAM
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

S&P 100 NEWS

> 21st Century Fox Inc

> Accenture PLC

> Allstate Corp.

> Altria Group, Inc.

> Amazon.com Inc

> American Express

> American International Group

> Anadarko Petroleum Corp.

> Bank of America

> Bank of New York Mellon Corp

> Baxter International

> Berkshire Hathaway Inc.

> Biogen Idec Inc

> BLACKROCK FDS

> Booking Holdings

> Bristol-Myers Squibb Co.

> Caterpillar Inc.

> Cisco Systems Inc

> Coca Cola Co.

> Colgate-Palmolive

> ConocoPhillips

> Costco Wholesale Corp

> CVS Caremark Corp.

> Danaher Corp.

> Devon Energy Corp

> Eli Lilly & Co.

> Emerson Electric Co.

> Exelon Corporation

> Exxon Mobil Corp.

> Ford Motor Company

> Freeport-McMoRan

> General Dynamics

> General Electric

> General Motors

> Gilead Sciences Inc

> Goldman Sachs Group, Inc.

> Halliburton Co.

> Hewlett-Packard Co.

> Home Depot, Inc

> Honeywell International, Inc.

> International Business Machines (IBM)

> Johnson & Johnson

> JP Morgan Chase & Co

> Kinder Morgan Inc

> Lockheed Martin

> Lowes Companies

> Mastercard Inc A

> McDonald's Corp.

> Medtronic, Inc.

> Merck & Co., Inc.

> ...

FEEDS

My Google

Microsoft Live

My Yahoo

COMPANY SEARCH RESULT

$Biogen Idec Inc: Click to view the issuer\'s details$

Last update : 21/08/2018 >View issuer details

2018.10.25 | 14:31 | Permanent Information Releases / General Company News

puce Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Conference - HTML (w)

2018.10.23 | 07:00 | Permanent Information Releases / General Company News

puce UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus - HTML (w)

2018.10.18 | 13:30 | Permanent Information Releases / General Company News

puce Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting - HTML (w)

2018.10.17 | 08:00 | Permanent Information Releases / General Company News

puce IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union - HTML (w)

2018.10.11 | 13:30 | Permanent Information Releases / General Company News

puce Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis - HTML (w)

2018.10.06 | 13:30 | Permanent Information Releases / General Company News

puce New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy - HTML (w)

2018.10.03 | 13:30 | Permanent Information Releases / General Company News

puce Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS) - HTML (w)

2018.10.02 | 13:30 | Permanent Information Releases / General Company News

puce Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care - HTML (w)

2018.09.04 | 13:30 | Permanent Information Releases / General Company News

puce Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction - HTML (w)

2018.08.28 | 13:30 | Permanent Information Releases / General Company News

puce Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab - HTML (w)

2018.07.25 | 23:08 | Permanent Information Releases / General Company News

puce Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2018 - HTML (w)

2018.07.25 | 16:30 | Permanent Information Releases / General Company News

puce Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2018 - HTML (w)

2018.07.24 | Periodic information / Half-Year Financial Report

puce Biogen Idec Inc : Second quarter 2018 - PDF (376Kb)

2018.07.18 | 13:30 | Permanent Information Releases / General Company News

puce Data to be Presented From Biogen's Alzheimer's Disease Clinical Development Portfolio at the 2018 Alzheimer's Association International Conference (AAIC) - HTML (w)

2018.07.06 | 01:30 | Permanent Information Releases / General Company News

puce Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months - HTML (w)

Pages : 1 - 2 - 3 / Doc nb : 36